Portal de Periódicos da CAPES

Emerging Affinity Reagents for High Throughput Proteomics

2019; Lippincott Williams & Wilkins; Volume: 140; Issue: 20 Linguagem: Inglês

10.1161/circulationaha.119.039912

1524-4539

Mark D. Benson, Debby Ngo, Peter Ganz, Robert E. Gerszten,

Advanced Biosensing Techniques and Applications

HomeCirculationVol. 140, No. 20Emerging Affinity Reagents for High Throughput Proteomics Free AccessArticle CommentaryPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessArticle CommentaryPDF/EPUBEmerging Affinity Reagents for High Throughput ProteomicsTrust, but Verify Mark D. Benson, MD, PhD, Debby Ngo, MD, Peter Ganz, MD and Robert E. Gerszten, MD Mark D. BensonMark D. Benson Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA (M.D.B., D.N., R.E.G.). Search for more papers by this author , Debby NgoDebby Ngo Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA (M.D.B., D.N., R.E.G.). Search for more papers by this author , Peter GanzPeter Ganz Division of Cardiology, Zuckerberg San Francisco General Hospital, University of California, San Francisco (P.G.). Search for more papers by this author and Robert E. GersztenRobert E. Gerszten Robert E. Gerszten, MD, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02115. Email E-mail Address: [email protected] Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA (M.D.B., D.N., R.E.G.). Search for more papers by this author Originally published11 Nov 2019https://doi.org/10.1161/CIRCULATIONAHA.119.039912Circulation. 2019;140:1610–1612High throughput proteomic profiling of human plasma is immensely challenging due to the extraordinary complexity and broad dynamic range of plasma protein concentrations. Mass spectrometry is unmatched for its ability to provide unambiguous identification of specific peptides, though its application to plasma proteomics at the population level remains prohibitive due to slow throughput and inability to quantify low abundant proteins without extensive upfront sample separation. ELISA-based approaches in turn have been limited by the unavailability of well-credentialed antibodies for many blood proteins and by issues with cross-reactivity, which significantly hampers the ability to multiplex antibodies for higher throughput analyses.To address these challenges, emerging proteomics technologies have integrated new types of affinity reagents to bind proteins. Single-stranded DNA aptamers are one such technology that has been recently leveraged for large-scale human plasma profiling.1,2 These short nucleotide segments (aptamers) fold into complex structures that bind protein targets through shape and charge complementarity with high affinity and specificity. Vast libraries that contain every possible sequence of these nucleotide segments can be randomly synthesized (typically containing ≈1014–1015 unique molecules) and exposed to a recombinant protein of interest. Through an iterative selection process, the aptamer with the best binding/capture properties can be selected and then amplified and tested for cross-reactivity, stability, and target binding properties.In the assay, aptamers can be highly multiplexed to serve as pull down reagents for several thousand protein targets at a time from complex samples (blood, cerebrospinal fluid, tissue homogenate, etc). Following a series of wash steps, each aptamer can then be released from its bound protein target, allowed to hybridize to a complementary sequence on a microarray DNA chip, and quantified by fluorescence. Thus, this technology efficiently translates protein concentrations to DNA concentrations, which can be measured using widely available molecular genetics approaches. Currently, DNA aptamers can quantify the levels of about 5000 different target proteins.With this technology now viable, the current crucial challenge in the field is to develop approaches to validate the specificity and selectivity of each of these new reagents. Complementary approaches, leveraging orthogonal techniques including mass spectrometry, functional genomics, and alternative affinity-based approaches, can all be used to systematically validate currently available aptamer reagents.In one such mass spectrometry−based approach, for example, individual aptamers can be immobilized on beads, incubated with a study sample, and then selectively eluted for analysis by liquid chromatography-tandem mass spectrometry. This not only allows for the determination of the limit of detection and limit of quantification of each aptamer of interest, but also provides important information regarding the analytic specificity of the aptamer.The application of high throughput protein affinity reagents to thousands of human samples also affords new ways to leverage available genetic information to explore aptamer specificity. Genetic association studies can be conducted on circulating levels of each aptamer-measured protein. Detection of a genetic variant located within the gene that encodes the measured protein provides strong orthogonal evidence that the aptamer is capturing its intended protein target, resulting in a valid quantitative assay. For example, we and others have demonstrated that a single nucleotide polymorphism (SNP; rs41271951) located within the cathepsin S gene is significantly associated with plasma levels of aptamer-measured cathepsin S protein, a cysteine protease involved in atherogenesis.3,4 This provides strong supporting evidence that the cathepsin S aptamer is indeed binding its intended cathepsin S target protein. Further, these protein-SNP data can provide useful biological insight. For example, in addition to the rs41271951 SNP that is predicted to result in a missense substitution within the well-studied signal peptide responsible for cathepsin S secretion efficiency, additional associated SNPs point toward novel regulatory mechanisms of circulating cathepsin S levels in plasma.Emerging technologies are beginning to allow for multiplexed antibody-based assays to be used to validate aptamer reagents in a systematic fashion. Oligonucleotide-labeled antibodies have recently been incorporated into a novel, commercially available platform (Olink) that can be used to quantify levels of over a thousand human proteins. As there is approximately a 50% overlap between protein targets that are included on this platform and the SOMAscan DNA aptamer-based platform, investigators can now systematically compare these complementary approaches.It is important to highlight that there are significant ongoing efforts to study and improve the specificity properties of novel affinity reagents themselves. For example, specific chemical side chains can be added to DNA aptamers in order to generate reagents with very slow off-rates that can withstand vigorous wash steps and thus reduce nonspecific binding. The inclusion of polyanionic competitor reagents during these wash steps (aptamers are also polyanions) further reduces binding of nonspecific proteins to these reagents. Oligonucleotide-labeled antibody reagents require pairwise binding of 2 probes in order to improve specificity. Leveraging these approaches, these affinity-based platforms can now discriminate between highly homologous proteoforms.Despite these ongoing efforts, some investigators have recently suggested that emerging affinity reagents for high throughput proteomics are not valuable until specificity and additional performance characteristics match those of clinical assays. Such a demand on performance ignores the value-add of these reagents to high throughput discovery, which, if desired, can be confirmed with targeted approaches, as detailed above. The challenges facing new affinity proteomic tools are reminiscent of criticisms in the early genome-wide association study era—when initial SNP arrays pointed only to loci of interest and clearly did not perform with Clinical Laboratory Improvement Amendments–ready clinical performance standards. These obstacles were overcome through advances in probe design, quality control procedures, experimental and statistical methods, and orthogonal validation. Consequently, early skepticism of this technology has been replaced by recognition of its potential to inform disease biology.These advances have allowed for significantly improved accessibility to proteomic profiling studies across a variety of experimental applications in large human cohorts. For example, investigators have recently applied the aptamer platform to nearly 2000 individuals across 2 large cohorts of patients with coronary heart disease to identify a signature of 9 plasma proteins associated with subsequent cardiovascular disease risk.2 Application of the same platform to nearly 500 baseline plasma samples from participants of the ILLUMINATE trial (Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events) recently identified a similar protein signal that predicted harm from the cholesterol ester transfer protein inhibitor torcetrapib.5 While these clinical applications provide important proof of concept for real-world clinical applications, validation in heterogeneous cohorts as well as assessment of how much this information adds to clinical findings are ongoing. Perhaps the most promising applications of these high throughput technologies relate to fundamental biology. By integrating proteomics and genomics, investigators have begun to identify the genetic architecture of plasma proteins and to uncover master regulators of the circulating proteome and disease-associated effectors leveraging Mendelian randomization strategies.3,4In sum, aptamers and oligonucleotide-labeled antibodies have opened the door to large-scale human proteomic profiling, with reproducibility and precision analogous to many molecular discovery tool. In parallel, continued appreciation for a multidisciplinary, collaborative approach, including public sharing of data, has contributed to remarkable progress to date, with the next central challenge in the field focused on developing systematic methods to evaluate and improve the technical sensitivity and selectivity of individual reagents. With great promise, yet clear recognition of affinity-based proteomics limitations and ongoing efforts to address them, we suggest a previously used guiding principle: “Trust, but verify…”Sources of FundingThis work was supported by the following grants: National Institutes of Health (NIH) R01HL132320, NIH R01HL133870, NIH R01HL144483, NIH R01 AG063507, and NIH U24DK112340.DisclosuresDr Ganz serves on a medical advisory board to SomaLogic, Inc, for which he accepts no salary, honoraria, or any other financial incentives. The other authors report no conflicts.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.https://www.ahajournals.org/journal/circRobert E. Gerszten, MD, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02115. Email [email protected]harvard.eduReferences1. Ngo D, Sinha S, Shen D, Kuhn EW, Keyes MJ, Shi X, Benson MD, O’Sullivan JF, Keshishian H, Farrell LA, et al. Aptamer-based proteomic profiling reveals novel candidate biomarkers and pathways in cardiovascular disease.Circulation. 2016; 134:270–285. doi: 10.1161/CIRCULATIONAHA.116.021803LinkGoogle Scholar2. Ganz P, Heidecker B, Hveem K, Jonasson C, Kato S, Segal MR, Sterling DG, Williams SA. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease.JAMA. 2016; 315:2532–2541. doi: 10.1001/jama.2016.5951CrossrefMedlineGoogle Scholar3. Benson MD, Yang Q, Ngo D, Zhu Y, Shen D, Farrell LA, Sinha S, Keyes MJ, Vasan RS, Larson MG, et al. Genetic architecture of the cardiovascular risk proteome.Circulation. 2018; 137:1158–1172. doi: 10.1161/CIRCULATIONAHA.117.029536LinkGoogle Scholar4. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T, Paige E, Surendran P, et al. Genomic atlas of the human plasma proteome.Nature. 2018; 558:73–79. doi: 10.1038/s41586-018-0175-2CrossrefMedlineGoogle Scholar5. Williams SA, Murthy AC, DeLisle RK, Hyde C, Malarstig A, Ostroff R, Weiss SJ, Segal MR, Ganz P. Improving assessment of drug safety through proteomics: early detection and mechanistic characterization of the unforeseen harmful effects of torcetrapib.Circulation. 2018; 137:999–1010. doi: 10.1161/CIRCULATIONAHA.117.028213LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Zhang G, Brown J, Quartararo A, Li C, Tan X, Hanna S, Antilla S, Cowfer A, Loas A and Pentelute B (2022) Rapid de novo discovery of peptidomimetic affinity reagents for human angiotensin converting enzyme 2, Communications Chemistry, 10.1038/s42004-022-00625-3, 5:1, Online publication date: 1-Dec-2022. Katz D and Thompson A (2022) Proteomics in Heart Failure: From Benchtop to Bedside, Journal of Cardiac Failure, 10.1016/j.cardfail.2021.12.003, 28:4, (601-603), Online publication date: 1-Apr-2022. Cooper L, Bruce S, Psotka M, Mentz R, Bell R, Seliger S, O'Connor C and deFilippi C (2022) Proteomic differences among patients with heart failure taking furosemide or torsemide, Clinical Cardiology, 10.1002/clc.23733, 45:3, (265-272), Online publication date: 1-Mar-2022. Katz D, Tahir U, Bick A, Pampana A, Ngo D, Benson M, Yu Z, Robbins J, Chen Z, Cruz D, Deng S, Farrell L, Sinha S, Schmaier A, Shen D, Gao Y, Hall M, Correa A, Tracy R, Durda P, Taylor K, Liu Y, Johnson W, Guo X, Yao J, Ida Chen Y, Manichaikul A, Jain D, Bouchard C, Sarzynski M, Rich S, Rotter J, Wang T, Wilson J, Natarajan P, Gerszten R, Abe N, Abecasis G, Aguet F, Albert C, Almasy L, Alonso A, Ament S, Anderson P, Anugu P, Applebaum-Bowden D, Ardlie K, Arking D, Arnett D, Ashley-Koch A, Aslibekyan S, Assimes T, Auer P, Avramopoulos D, Ayas N, Balasubramanian A, Barnard J, Barnes K, Barr R, Barron-Casella E, Barwick L, Beaty T, Beck G, Becker D, Becker L, Beer R, Beitelshees A, Benjamin E, Benos T, Bezerra M, Bielak L, Bis J, Blackwell T, Blangero J, Boerwinkle E, Bowden D, Bowler R, Brody J, Broeckel U, Broome J, Brown D, Bunting K, Burchard E, Bustamante C, Buth E, Cade B, Cardwell J, Carey V, Carrier J, Carson A, Carty C, Casaburi R, Casas Romero J, Casella J, Castaldi P, Chaffin M, Chang C, Chang Y, Chasman D, Chavan S, Chen B, Chen W, Chen Y, Cho M, Choi S, Chuang L, Chung M, Chung R, Clish C, Comhair S, Conomos M, Cornell E, Correa A, Crandall C, Crapo J, Cupples L, Curran J, Curtis J, Custer B, Damcott C, Darbar D, David S, Davis C, Daya M, de Andrade M, de las Fuentes L, de Vries P, DeBaun M, Deka R, DeMeo D, Devine S, Dinh H, Doddapaneni H, Duan Q, Dugan-Perez S, Duggirala R, Durda J, Dutcher S, Eaton C, Ekunwe L, El Boueiz A, Ellinor P, Emery L, Erzurum S, Farber C, Farek J, Fingerlin T, Flickinger M, Fornage M, Franceschini N, Frazar C, Fu M, Fullerton S, Fulton L, Gabriel S, Gan W, Gao S, Gao Y, Gass M, Geiger H, Gelb B, Geraci M, Germer S, Gerszten R, Ghosh A, Gibbs R, Gignoux C, Gladwin M, Glahn D, Gogarten S, Gong D, Goring H, Graw S, Gray K, Grine D, Gross C, Gu C, Guan Y, Guo X, Gupta N, Haas D, Haessler J, Hall M, Han Y, Hanly P, Harris D, Hawley N, He J, Heavner B, Heckbert S, Hernandez R, Herrington D, Hersh C, Hidalgo B, Hixson J, Hobbs B, Hokanson J, Hong E, Hoth K, Hsiung C, Hu J, Hung Y, Huston H, Hwu C, Irvin M, Jackson R, Jain D, Jaquish C, Johnsen J, Johnson A, Johnson C, Johnston R, Jones K, Kang H, Kaplan R, Kardia S, Kelly S, Kenny E, Kessler M, Khan A, Khan Z, Kim W, Kimoff J, Kinney G, Konkle B, Kooperberg C, Kramer H, Lange C, Lange E, Lange L, Laurie C, Laurie C, LeBoff M, Lee J, Lee S, Lee W, LeFaive J, Levine D, Levy D, Lewis J, Li X, Li Y, Lin H, Lin H, Lin X, Liu S, Liu Y, Liu Y, Loos R, Lubitz S, Lunetta K, Luo J, Magalang U, Mahaney M, Make B, Manichaikul A, Manning A, Manson J, Martin L, Marton M, Mathai S, Mathias R, May S, McArdle P, McDonald M, McFarland S, McGarvey S, McGoldrick D, McHugh C, McNeil B, Mei H, Meigs J, Menon V, Mestroni L, Metcalf G, Meyers D, Mignot E, Mikulla J, Min N, Minear M, Minster R, Mitchell B, Moll M, Momin Z, Montasser M, Montgomery C, Muzny D, Mychaleckyj J, Nadkarni G, Naik R, Naseri T, Natarajan P, Nekhai S, Nelson S, Neltner B, Nessner C, Nickerson D, Nkechinyere O, North K, O’Connell J, O’Connor T, Ochs-Balcom H, Okwuonu G, Pack A, Paik D, Palmer N, Pankow J, Papanicolaou G, Parker C, Peloso G, Peralta J, Perez M, Perry J, Peters U, Peyser P, Phillips L, Pleiness J, Pollin T, Post W, Powers Becker J, Preethi Boorgula M, Preuss M, Psaty B, Qasba P, Qiao D, Qin Z, Rafaels N, Raffield L, Rajendran M, Ramachandran V, Rao D, Rasmussen-Torvik L, Ratan A, Redline S, Reed R, Reeves C, Regan E, Reiner A, Reupena M, Rice K, Rich S, Robillard R, Robine N, Roden D, Roselli C, Rotter J, Ruczinski I, Runnels A, Russell P, Ruuska S, Ryan K, Sabino E, Saleheen D, Salimi S, Salvi S, Salzberg S, Sandow K, Sankaran V, Santibanez J, Schwander K, Schwartz D, Sciurba F, Seidman C, Seidman J, Sériès F, Sheehan V, Sherman S, Shetty A, Shetty A, Sheu W, Shoemaker M, Silver B, Silverman E, Skomro R, Smith A, Smith J, Smith J, Smith N, Smith T, Smoller S, Snively B, Snyder M, Sofer T, Sotoodehnia N, Stilp A, Storm G, Streeten E, Su J, Sung Y, Sylvia J, Szpiro A, Taliun D, Tang H, Taub M, Taylor K, Taylor M, Taylor S, Telen M, Thornton T, Threlkeld M, Tinker L, Tirschwell D, Tishkoff S, Tiwari H, Tong C, Tracy R, Tsai M, Vaidya D, Van Den Berg D, VandeHaar P, Vrieze S, Walker T, Wallace R, Walts A, Wang F, Wang H, Wang J, Watson K, Watt J, Weeks D, Weinstock J, Weir B, Weiss S, Weng L, Wessel J, Willer C, Williams K, Williams L, Wilson C, Wilson J, Winterkorn L, Wong Q, Wu J, Xu H, Yanek L, Yang I, Yu K, Zekavat S, Zhang Y, Zhao S, Zhao W, Zhu X, Zody M and Zoellner S (2021) Whole Genome Sequence Analysis of the Plasma Proteome in Black Adults Provides Novel Insights Into Cardiovascular Disease, Circulation, 145:5, (357-370), Online publication date: 1-Feb-2022. Fankhauser R, DePatie N, Berryman R, Lucero O and Kulkarni R (2022) Proteomic biomarker technology for cancer immunotherapy Engineering Technologies and Clinical Translation, 10.1016/B978-0-323-90949-5.00007-3, (357-397), . Bruno V, Lindau R, Jenmalm M, Ticconi C, Piccione E, Pietropolli A and Ernerudh J (2020) First‐trimester trophoblasts obtained by chorionic villus sampling maintain tolerogenic and proteomic features in successful pregnancies despite a history of unexplained recurrent pregnancy loss, American Journal of Reproductive Immunology, 10.1111/aji.13314, 84:6, Online publication date: 1-Dec-2020. Orwoll E, Wiedrick J, Nielson C, Jacobs J, Baker E, Piehowski P, Petyuk V, Gao Y, Shi T, Smith R, Bauer D, Cummings S and Lapidus J (2020) Proteomic assessment of serum biomarkers of longevity in older men, Aging Cell, 10.1111/acel.13253, 19:11, Online publication date: 1-Nov-2020. Ganz P, Deo R and Dubin R (2020) Proteomics for personalized cardiovascular risk assessment: in pursuit of the Holy Grail, European Heart Journal, 10.1093/eurheartj/ehaa661, 41:41, (4008-4010), Online publication date: 1-Nov-2020. November 12, 2019Vol 140, Issue 20 Advertisement Article InformationMetrics © 2019 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.119.039912PMID: 31710523 Originally publishedNovember 11, 2019 Keywordsaptamers, nucleotideproteomicsmass spectrometryPDF download Advertisement SubjectsBiomarkersOmicsProteomics